Low-energy Shock Wave Therapy-A Novel Treatment Option for Erectile Dysfunction in Men With Cardiovascular Disease

被引：9

作者：

Kalka, Dariusz ^{[1
]}

Gebala, Jana

Smolinski, Ryszard

Rusiecki, Leslaw

Pilecki, Witold

Zdrojowy, Romuald

机构：

[1] Wroclaw Med Univ, Cardiosexol Unit, Dept Pathophysiol, Ul K Marcinkowskiego 1, PL-50368 Wroclaw, Poland

来源：

UROLOGY | 2017年 / 109卷

关键词：

DOUBLE-BLIND; CLINICAL-TRIAL; HEART-DISEASE; EFFICACY; SAFETY; SILDENAFIL; TADALAFIL; NONRESPONDERS; MULTICENTER; RESPOND;

D O I：

10.1016/j.urology.2017.05.030

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

Patients with cardiovascular disease (CVD) are prone to developing erectile dysfunction (ED) owing to the common risk factors and pathogenesis underlying ED and CVD. As a result, ED affects nearly 80% of male patients with CVD. The efficacy of phosphodiesterase type 5 inhibitors, vacuum erection devices, or intracavernosal injection of vasodilating agents is well established in the treatment of ED; however, their use is limited. Low-energy shock wave therapy is a novel modality that may become a causative treatment for ED. This review aims to assess the efficacy and safety of low-energy shock wave therapy in the treatment of ED in men with CVD. (C) 2017 Elsevier Inc.

引用

页码：19 / 26

页数：8

共 50 条

[1] Twelve-Month Efficacy and Safety of Low-Intensity Shockwave Therapy for Erectile Dysfunction in Patients Who Do Not Respond to Phosphodiesterase Type 5 Inhibitors [J].